Are Proton-Pump Inhibitors Associated with Increased COVID-19 Risk?

An online survey suggests a dose-dependent association between PPI use and risk for testing positive for COVID-19.

Proton-pump inhibitors (PPIs) have become a mainstay in the treatment of acid-related conditions. They were initially felt to be very safe, but multiple studies published in the past several years show associations with increased risks for both infectious and noninfectious conditions, particularly when taken at higher-than-indicated dosages. This is the first report of an increased risk for COVID-19 test positivity in PPI users.

In a population-based online survey conducted in the U.S. in May and June 2020, 53,130 adults noted ever having upper GI symptoms. Among them, 3386 (6.4%) reported having received a positive COVID-19 test. A regression model found an odds ratio of 2.15 for having a positive COVID-19 test in those on once-daily PPIs a…

Reviewing Author

Kenneth R. DeVault, MD

Disclosures

Consultant/Advisory BoardPhathom Pharmaceuticals

Grant/Research SupportIronwood Pharmaceuticals

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology Education Universe (Co-Editor)

Kenneth R. DeVault, MD

Disclosures

Consultant/Advisory BoardPhathom Pharmaceuticals

Grant/Research SupportIronwood Pharmaceuticals

Leadership Positions in Professional SocietiesAmerican College of Gastroenterology Education Universe (Co-Editor)

Are Proton-Pump Inhibitors Associated with Increased COVID-19 Risk?

Topics

Reviewing Author